{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:26:09Z","timestamp":1749947169317},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1097\/md.0000000000008337","type":"journal-article","created":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T18:52:08Z","timestamp":1508957528000},"page":"e8337","source":"Crossref","is-referenced-by-count":8,"title":["Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia"],"prefix":"10.1097","volume":"96","author":[{"given":"Yayue","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yigai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-34-20210226","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukemia: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemia. Proposals by the French-American-British Cooperative Leukemia Group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"key":"R2-34-20210226","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"R3-34-20210226","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"R4-34-20210226","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.beha.2013.09.006","article-title":"Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?","volume":"26","author":"Itzkson","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"R5-34-20210226","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/ejh.12393","article-title":"Immune thrombocytopenia in chronic myelomonocytic leukemia","volume":"93","author":"Hadjadj","year":"2014","journal-title":"Eur J Haematol"},{"key":"R6-34-20210226","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1080\/1042819021000016186","article-title":"Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"43","author":"Saif","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"R7-34-20210226","first-page":"721","article-title":"Rheumatic manifestations in myelodysplastic syndromes","volume":"18","author":"Castro","year":"1991","journal-title":"J Rheumatol"},{"key":"R8-34-20210226","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2141.1995.tb05310.x","article-title":"Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy","volume":"91","author":"Enright","year":"1995","journal-title":"Br J Haematol"},{"key":"R9-34-20210226","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/ard.2003.012948","article-title":"Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression","volume":"63","author":"Giannouli","year":"2004","journal-title":"Ann Rheum"},{"key":"R10-34-20210226","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3324\/haematol.11812","article-title":"Activation of cytotoxic T-cell receptor gammadelta T lymphocytesin response to specific stimulation in myelodysplastic syndromes","volume":"93","author":"Kiladjian","year":"2008","journal-title":"Haematologica"},{"key":"R11-34-20210226","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.leukres.2006.11.007","article-title":"Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile","volume":"31","author":"Ma","year":"2007","journal-title":"Leuk Res"},{"key":"R12-34-20210226","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/sj.leu.2402129","article-title":"Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases","volume":"15","author":"Bourgeois","year":"2001","journal-title":"Leukemia"},{"key":"R13-34-20210226","first-page":"609","article-title":"Chronic myelomonocytic leukemia developed 9 years after the diagnosis of idiopathic thrombocytopenic purpura in a child","volume":"35","author":"Fukuda","year":"1994","journal-title":"Rinsho Ketsueki"},{"key":"R14-34-20210226","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1365-2257.2002.00454.x","article-title":"Not all cases of idiopathic thrombocytopenic purpura are what they might first seem","volume":"24","author":"Mainwaring","year":"2002","journal-title":"Clin Lab Haematol"},{"key":"R15-34-20210226","first-page":"222","article-title":"Chronic myelomonocytic leukemia developed 7 years after the onset of idiopathic thrombocytopenic purpura like syndrome","volume":"38","author":"Sawanobori","year":"1997","journal-title":"Rinsho Ketsueki"},{"key":"R16-34-20210226","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s12325-015-0251-z","article-title":"Current management of primary immune thrombocytopenia","volume":"32","author":"Provan","year":"2015","journal-title":"Adv Ther"},{"key":"R17-34-20210226","first-page":"76","article-title":"Corticosteroids and monocytosis","volume":"125","author":"Barker","year":"2012","journal-title":"N Z Med J"},{"key":"R18-34-20210226","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"key":"R19-34-20210226","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood-2009-04-219493","article-title":"Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"114","author":"Will","year":"2009","journal-title":"Blood"},{"key":"R20-34-20210226","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.leukres.2010.06.029","article-title":"Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome","volume":"35","author":"Mavroudi","year":"2011","journal-title":"Leuk Res"},{"key":"R21-34-20210226","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.seminhematol.2014.10.005","article-title":"Treatment of myelodysplastic syndrome with thrombomimetic drugs","volume":"52","author":"Santini","year":"2015","journal-title":"Semin Hematol"},{"key":"R22-34-20210226","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/1078155214544076","article-title":"Successful treatment of severe thrombocytopenia with the use of thrombopoietin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia","volume":"21","author":"Modi","year":"2015","journal-title":"J Oncol Pharm Pract"},{"key":"R23-34-20210226","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.clml.2016.02.009","article-title":"Eltrombopag use in patients with chronic myelomonocytic leukemia (CMML): a cautionary tale","volume":"16","author":"Ramadan","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R24-34-20210226","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s12185-013-1401-1","article-title":"Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study","volume":"98","author":"Katsutani","year":"2013","journal-title":"Int J Hematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:37:11Z","timestamp":1620959831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201710270-00034"}},"subtitle":["Two cases reports A CARE-compliant article"],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":24,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008337","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}